Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03620643|
Recruitment Status : Recruiting
First Posted : August 8, 2018
Last Update Posted : January 6, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Lobular Breast Carcinoma Gastric Cancer Triple Negative Breast Cancer CDH1 Gene Mutation||Drug: Crizotinib Oral Capsule [Xalkori] Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]||Phase 2|
This clinical study is looking at whether a drug called crizotinib, which is used in some patients with lung cancer, is effective in a sub-type of breast cancer, called lobular breast cancer. As the majority of lobular breast cancers are oestrogen receptor positive (ER+ve), crizotinib will be combined with a second drug, fulvestrant, to try to block tumour growth that is driven by oestrogen.
Crizotinib targets cancers with genetic changes in two genes called ALK and ROS1. Lung cancers with changes in these genes usually get smaller when treated with crizotinib. Laboratory work at the Institute of Cancer Research has shown that lobular breast cancer cells, due to a mutation in a different gene called CDH1, appear to be similarly affected by crizotinib.
Fulvestrant is an oestrogen receptor down regulator and blocks the effects of oestrogen on oestrogen receptor positive (ER+ve) breast cancer cells. Fulvestrant is an established and approved anti-hormone therapy which patients with breast cancers are receiving in the clinic. It is possible that the combination of crizotinib and an anti-oestrogen agent will shrink the tumour(s) more effectively and prevent further growth. Because fulvestrant is only effective in post-menopausal women, if participants have not yet gone through the menopause, participants will need to start (or continue to receive) a monthly injection under the skin to temporarily stop the function of the participants ovaries to be eligible to take part in the trial.
This injection is called goserelin and has to be started at least 4 weeks before the first day of treatment on the trial.
The overall aims of this clinical study are to find out:
- The proportion of patients whose tumour(s) shrink when they are treated with crizotinib and fulvestrant
- The safety and tolerability of fulvestrant in combination with crizotinib, to determine that they can be given together without unacceptable side effects
- What the drugs do to the tumours, which will help us decide which patients may benefit from this combination in the future
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||58 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||This multi-centre study design will aim to complete recruitment over 18 months from six high volume centres including the Royal Marsden. Parallel recruitment to breast and basket cancer cohorts will take place for this study.|
|Official Title:||Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours|
|Actual Study Start Date :||May 9, 2019|
|Estimated Primary Completion Date :||May 1, 2023|
|Estimated Study Completion Date :||July 1, 2024|
Active Comparator: Crizotinib Oral Capsule [Xalkori] monotherapy
Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule [Xalkori] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
Drug: Crizotinib Oral Capsule [Xalkori]
Crizotinib 250 mg Crizotinib 200mg
Other Name: Xalkori
Active Comparator: Crizotinib Oral Capsule [Xalkori] plus Fulvestrant injection
Arm 2 - Lobular Breast Cancer cohort (n=29 participants) will be treated with combination therapy. The combination therapy includes; Crizotinib Oral Capsule [Xalkori] (250mg b.d.) plus Fulvestrant 50 mg/mL Prefilled Syringe [Faslodex or generic] intramuscular (IM) injection (500 mg per 1 cycle (q28 days, plus loading dose on day 15).
Drug: Crizotinib Oral Capsule [Xalkori]
Crizotinib 250 mg Crizotinib 200mg
Other Name: Xalkori
Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
Other Name: Faslodex
- Percentage of Breast Cancer Cohort Participants With Objective Response Assessed Using RECIST v1.1 [ Time Frame: From Day 1 to Progressive Disease, assessed up to end of study (up to approximately 48 months) ]To assess confirmed response rate by RECIST 1.1 of crizotinib and fulvestrant in advanced E-cadherin negative, ER positive lobular breast cancer.
- Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1 [ Time Frame: From Day 1 to Progressive Disease, assessed up to end of study (up to approximately 48 months) ]To assess confirmed response rate by RECIST 1.1 of crizotinib monotherapy in advanced E-cadherin negative, diffuse gastric cancer, triple negative lobular breast cancer or CDH1-mutated solid tumour.
- Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) [ Time Frame: From Day 1 to 90 days after last dose of study drug, assessed up to end of study (up to approximately 45 months) ]To assess the overall safety and tolerability of crizotinib with fulvestrant in the breast cancer cohort and as monotherapy in the basket cancer cohort. Toxicity will be assessed by CTCAE (version 4) every 4 weeks during study treatment. Adverse events, including serious adverse events, will be recorded until 30 days after the last dose of study treatment with crizotinib.
- Progression-free survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in both gastric and breast cancer cohorts [ Time Frame: From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (up to approximately 48 months) ]PFS is defined as the time from baseline treatment to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (>/=) 20 percent (%) relative increase and >/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.
- Assessment of overall survival in each cohort [ Time Frame: From Day 1 to disease progression (PD) or death from any cause, assessed up to end of study (up to approximately 48 months) ]Overall survival, calculated from day 1 of study treatment to the date of death from any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients with histological diagnosis of E-cadherin negative inoperable or metastatic diffuse gastric cancer (basket cohort), Or inoperable or metastatic triple negative lobular breast cancer (basket cohort) Or inoperable or metastatic CDH1-mutated solid tumour with allele fraction ≥20% (basket cohort) Or recurrent inoperable locally advanced ER positive/HER2 negative lobular breast cancer (breast cohort).
Assessment of E-cadherin, ER and HER2 status as per local assessment.
- Lobular breast cancer patients previously treated with at least one prior line of therapy including at least one prior line of hormone therapy for advanced disease, but no more than three prior lines of chemotherapy for advanced disease.
Gastric cancer, triple negative lobular breast cancer or CDH1-mutated solid tumour patients previously treated with at least one prior therapy for advanced disease OR relapsing within one year of completing (neo) adjuvant chemotherapy OR unsuitable for chemotherapy in the opinion of the investigator (for example patient choice not to have chemotherapy, or no suitable chemotherapy agent).
- Measurable disease (RECIST 1.1)
- Haematological and biochemical indices within the ranges shown in protocol. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes in the trial.
- Female patients with child-bearing potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial. Both male and female patients of reproductive potential must agree to use two forms of highly effective contraception (see below) for 2 weeks before starting the study treatment, throughout the treatment period and for 90 days after discontinuation of treatment with crizotinib and 2 years after the last dose of fulvestrant.
NOTE: it is only considered highly effective if the patient is refraining from sexual intercourse during the entire period of risk associated with the study treatments
The oral contraceptive pill may be ineffective when taken with crizotinib so is not an acceptable means of contraception for female patients during this study but can be used by female partners of male patients.
- 18 years of age or over with written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.
- World Health Organisation (WHO) performance status 0,1 or 2
- Estimated life expectancy of at least 3 months in the opinion of the investigator
- Pre-/peri-menopausal ER+ lobular breast cancer patients must be willing to receive gosarelin injections every 28 days.
- Signed and dated informed consent.
- Patients willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.
- Systemic chemotherapy or investigational medicinal products during the previous four weeks, or hormonal therapy within 7 days except luteinizing hormone-releasing hormone (LHRH) analogues for ovarian suppression. Bisphosphonates or RANK ligand antagonists are permitted for the management of bone metastases.
- Previous treatment with any agent that inhibits ROS1
- Mixed ductal/lobular breast cancer, unless both ductal and lobular components are CDH1 negative by local assessment
- Major surgery (excluding minor procedures, e.g. placement of vascular access) within 4 weeks or radiation therapy within 14 days prior to study entry
- Patients with known symptomatic brain metastases requiring steroids, untreated brain metastases or spinal cord compression
- Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack. Uncontrolled hypertension or cardiac dysrhythmia including atrial fibrillation.
- QT interval, corrected >470 ms or the use of bradycardic agents, drugs which prolong the QT interval and/or anti-arrhythmic agents within 12 days before the first dose of crizotinib or during study treatment.
- Use of drugs that are known potent cytochrome P450 (CYP) 3A4 inhibitors or moderate or strong CYP 3A4 inducers within 12 days before the first dose of crizotinib. Us of CYP3A4 substrates with a narrow therapeutic index (such as ciclosporin) is also not permitted within 12 days prior or during the study treatment.
- Patients on warfarin. Patients requiring anticoagulation for rate-controlled AF or previous venous thromboembolism should be switched to low-molecular weight heparin.
- Known HIV or AIDS-related illness, active infection requiring systemic therapy, or positive HBV or HCV test indicating acute or chronic infection.
- Inability or unwillingness to swallow pills, or (for patients receiving fulvestrant) receive IM injections.
- Other severe acute or chronic medical condition or psychiatric condition, recent or active suicidal ideation or behaviour, or end stage renal disease on haemodialysis, or laboratory abnormality that may increase the risk associated with study participation or investigational products administration or may interfere with the interpretation of results and, in the judgment of the Investigator, would make the patient inappropriate study entry.
- Persisting toxicity related to prior therapy >Grade 1 (except for stable peripheral neuropathy grade ≤2 or alopecia grade ≤2).
- Pregnancy or lactation.
- Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ≤6) prostate cancer.
- Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this study. Participation in an observational trial would be acceptable.
- Immunocompromised status due to current known active infection with HIV or due to the use of immunosuppressive therapies for other conditions
- Known prior or suspected hypersensitivity to investigational products or to any of the excipients.
- Patients at risk for gastrointestinal perforation (due to e.g., history of diverticulitis).
- Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03620643
|Contact: Rebecca Ruizfirstname.lastname@example.org|
|Contact: Alicia Okines||020 7811 8100||Alicia.Okines@rmh.nhs.uk|
|Beatson West of Scotland Cancer Centre||Recruiting|
|Glasgow, United Kingdom|
|Principal Investigator: Dr Iain MacPherson|
|St Luke's Cancer Centre||Withdrawn|
|Guildford, United Kingdom|
|Clatterbridge Cancer Centre||Withdrawn|
|Liverpool, United Kingdom|
|Royal Marsden NHS Foundation Trust||Recruiting|
|London, United Kingdom, SW3 6JJ|
|Contact: Alicia Okines 020 7811 8100 Alicia.Okines@rmh.nhs.uk|
|Principal Investigator: Dr Alicia Okines|
|Guys and St Thomas NHS Foundation Trust||Recruiting|
|London, United Kingdom|
|Principal Investigator: Professor Elinor Sawyer|
|University College London Hospital||Recruiting|
|London, United Kingdom|
|Principal Investigator: Dr Rebecca Roylance|
|The Christie NHS Foundation Trust||Recruiting|
|Manchester, United Kingdom|
|Principal Investigator: Dr Anne Armstrong|
|Study Chair:||Professor Peter Schmid||St Bart's Hospital|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Royal Marsden NHS Foundation Trust|
|Other Study ID Numbers:||
|First Posted:||August 8, 2018 Key Record Dates|
|Last Update Posted:||January 6, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Advanced E-cadherin negative gastric cancer
Oestrogen receptor positive lobular breast cancer
Triple Negative Breast Neoplasms
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Ductal, Lobular, and Medullary
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action